Serum biomarker screening for the diagnosis of early gastric cancer using SELDI-TOF-MS

Li, Ping; Zhang, Dianliang; Guo, Chunbao

doi:10.3892/mmr.2012.834

Cited by 7 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, most potential biomarkers were obtained by comparison between cancer and normal controls 19 , 42 - 44 , and their clinical diagnosis performance are usually affected by some benign diseases. In this study, we not only compared the levels of six targeted phospholipids between controls, benign diseases, and corresponding cancer, but also between different diseases originated from four types of organ.…”

Section: Discussionmentioning

confidence: 99%

Simultaneous Quantification of Serum Multi-Phospholipids as Potential Biomarkers for Differentiating Different Pathophysiological states of lung, stomach, intestine, and pancreas

Guo¹,

Ren²,

Li³

et al. 2017

J. Cancer

View full text Add to dashboard Cite

Background: Aberrant lipid metabolism is closely associated with cancer.Materials & Methods: Serum levels of sphingomyelins (SM) (34:1), phosphatidylcholine (PC) (34:2), PC(34:1), PC(36:4), PC(36:3), and PC(36:2) in 1449 serum samples (including 599 normal controls, 69 patients with benign lung diseases (BLDs), 61 with benign colorectal diseases, 54 with benign gastric diseases, 67 with benign pancreatic diseases, and 246 with lung cancer (LC), 144 with colorectal cancer, 94 with gastric cancer, 115 with pancreatic cancer) were quantified simultaneously based on their respective calibration equations with correlation coefficient of >0.98.Results: Receiver operating characteristic (ROC) analysis indicated that 18 panels obtained from these six phospholipids have high diagnostic ability to differentiate between different pathophysiological states. For example, a combination of SM(34:1), PC(34:2), PC(34:1), PC(36:3), and PC(36:2) to differentiating male patients with early stage LC from male normal controls plus male BLDs with a value under ROC curve (AUC) of 0.957, a sensitivity of 88.9%, and a specificity of 90.8%. SM(34:1) and PC(34:1) to differentiating female patients with early stage LC from female normal controls plus female BLDs with an AUC of 0.903, a sensitivity of 90.0%, and a specificity of 77.5%.Conclusion: Change trends of these six phospholipids were significantly correlated with gender, physiological states, and cancer stages.

show abstract

Section: Discussionmentioning

confidence: 99%

Simultaneous Quantification of Serum Multi-Phospholipids as Potential Biomarkers for Differentiating Different Pathophysiological states of lung, stomach, intestine, and pancreas

Guo¹,

Ren²,

Li³

et al. 2017

J. Cancer

View full text Add to dashboard Cite

show abstract

“…GC patients are often diagnosed after the disease has progressed to the advanced stage where the long term outlook is very poor (5-year survival rate of 10%–20%) [ 3 , 6 , 7 ]. Common methods for detecting GC are endoscopy and biopsy, which are both time-consuming and invasive, and can only identify the disease at a relatively late stage [ 8 ]. Moreover, these traditional detection methods are costly and not suitable for large-scale preventive screening [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Unraveling Molecular Differences of Gastric Cancer by Label-Free Quantitative Proteomics Analysis

Dai

Wang

Jing

et al. 2016

IJMS

View full text Add to dashboard Cite

Gastric cancer (GC) has significant morbidity and mortality worldwide and especially in China. Its molecular pathogenesis has not been thoroughly elaborated. The acknowledged biomarkers for diagnosis, prognosis, recurrence monitoring and treatment are lacking. Proteins from matched pairs of human GC and adjacent tissues were analyzed by a coupled label-free Mass Spectrometry (MS) approach, followed by functional annotation with software analysis. Nano-LC-MS/MS, quantitative real-time polymerase chain reaction (qRT-PCR), western blot and immunohistochemistry were used to validate dysregulated proteins. One hundred forty-six dysregulated proteins with more than twofold expressions were quantified, 22 of which were first reported to be relevant with GC. Most of them were involved in cancers and gastrointestinal disease. The expression of a panel of four upregulated nucleic acid binding proteins, heterogeneous nuclear ribonucleoprotein hnRNPA2B1, hnRNPD, hnRNPL and Y-box binding protein 1 (YBX-1) were validated by Nano-LC-MS/MS, qRT-PCR, western blot and immunohistochemistry assays in ten GC patients’ tissues. They were located in the keynotes of a predicted interaction network and might play important roles in abnormal cell growth. The label-free quantitative proteomic approach provides a deeper understanding and novel insight into GC-related molecular changes and possible mechanisms. It also provides some potential biomarkers for clinical diagnosis.

show abstract

“…Technical problems include selecting the best proteomics method for serum biomarker discovery [ 5 ]. Potential proteomic biomarkers can be notably determined through SELDI-TOF-MS [ 39 , 40 ]. SELDI-TOF-MS is a widely used technique for diagnostic biomarker discovery in plasma, serum, and tissue and has the ability to carry out screening and identification.…”

Section: Discussionmentioning

confidence: 99%

Determination of Serum Lost Goodwill Target Proteome in Patients with Severe Traumatic Brain Injury

Zhang

et al. 2015

BioMed Research International

View full text Add to dashboard Cite

show abstract

Serum biomarker screening for the diagnosis of early gastric cancer using SELDI-TOF-MS

Cited by 7 publications

References 21 publications

Simultaneous Quantification of Serum Multi-Phospholipids as Potential Biomarkers for Differentiating Different Pathophysiological states of lung, stomach, intestine, and pancreas

Simultaneous Quantification of Serum Multi-Phospholipids as Potential Biomarkers for Differentiating Different Pathophysiological states of lung, stomach, intestine, and pancreas

Unraveling Molecular Differences of Gastric Cancer by Label-Free Quantitative Proteomics Analysis

Determination of Serum Lost Goodwill Target Proteome in Patients with Severe Traumatic Brain Injury

Contact Info

Product

Resources

About